A Little STFU Story
LogicBio had closed on Friday with what appeared to be dim prospects. The company had received
notice that it would be delisted from NASDAQ because it had failed to meet the exchange's $1.00 minimum bid requirement. The stock closed on Friday at about USD 27¢.
Although I completely disapprove of Bioasis's investor relations, disclosure and guidance messaging, the possibility remains that if xB3 works, as suggested for over 14 years by Bioasis, then the company could be worth a lot of money. During that time we've seen chrispi, myself, and others ridiculed by some shareholders and the many Bioasis trolls for daring to point out that regardless of where we're at today, that true value for a compelling technology could be achieved.
In particular, chrispi has shown us several companies that have gone from rags to riches in the turn of a deal or upon a good press release. The same holds true for Bioasis. Bioasis investors might want to consider that almost all of the large pharmas and an untold number of small biotechs are engaged in gene therapy R&D, that there is still room for this type of deal where a company in trouble could nevertheless be acquired at a good premium to current value. In the end, value is all about the technology.
Unlike LogicBio, which is one of dozens of gene therapy players, Bioasis is one of only three or four companies with BBB transport technologies, and that xB3's unique qualities may ultimately position it at the top of the wide-open BBB space. Safe and effective transport of payloads across the blood-brain barrier is a unique and valuable accomplishment, and the two or three players that can do it will be worth a lot, as the almost $4 billion market cap of Denali proves.
I understand that some of you are completely unable to publicly accept any notion of success at Bioasis. Fortunately, success at Bioasis is entirely uninfluenced by anything you think or post. xB3 will be proven to work or not work, and its value and the Bioasis share price will be governed completely by whichever of those outcomes is true.
Some of you remember that Mark Day came from Alexion, and that Alexion's former leadership apparently did have a look at xB3 data, probably from Scarpa. Daiichi Sankyo, AstraZeneca's Enhertu partner, paid for a wee peek at xB3. I don't think their specific interest may come to anything. But it can't be a bad thing that Daiichi Sankyo, Alexion, and AstraZeneca are all aware of Bioasis and xB3. If xB3 really does work then it offers opportunities that no company will be able to resist.
667% premium on the previous close. It's probably a good idea to keep that in mind. Right, chrispi, my old friend?
jd